Thus, targeted deletion or neutralization of T cells that produce IL-12 and/or IL-23 or cell therapy based on administering regulatory B cells (Breg) or T cells (Treg) that produce IL-27 or IL-35 has been found to be effective in suppressing experimental autoimmune uveitis (EAU) and experimental autoimmune encephalomyelitis (EAE) that serve as mouse models of uveitis and MS, respectively [9,10]. The gene discussed is IL27; the disease is myeloid sarcoma.